Adverse events of prophylactic anti-influenza agents in medical staffs

Publication date: Available online 3 August 2017
Source:Journal of Infection and Chemotherapy
Author(s): Hideo Kato, Mao Hagihara, Yukiko Kato, Ai Kurumiya, Tomoko Takahashi, Miki Sakata, Naoya Nishiyama, Nobuhiro Asai, Yusuke Koizumi, Tatsuro Furui, Yuka Yamagishi, Hiroshige Mikamo
BackgroundWe undertook a survey to evaluate the compliance and the tolerability of oseltamivir and zanamivir when they were used as post-exposure prophylaxis among the medical staffs in the 2014–2015 seasons to understand a characteristic of adverse events caused by anti-influenza (flu) agents.Materials and MethodsDuring the study period, 540 medical staffs received oseltamivir (75 mg twice a day for 5 days) or zanamivir (twice a day for 5 days) as post-exposure prophylaxis of influenza, respectively.ResultsFour hundred eleven medical staffs of 540 medical staffs (76.1%) provided responses to questionnaire investigations. The adverse events caused by oseltamivir were reported by 86 of 382 medical staffs (22.5%). The most frequent adverse events were gastrointestinal adverse events (13.4%), followed by systemic and local diseases (11.8%), diseases of the nervous system (7.9%) and neuropsychiatric adverse events (0.5%). On the other hand, adverse events caused by zanamivir were reported by one (3.4%) of 29 medical staffs.ConclusionOur survey revealed that 22.5% subjects experienced any adverse events due to oseltamivir. And the regimen showed low compliance than we expected. On the other hands, zanamivir showed high adherence with lower incidence of adverse events.



from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2wbl0sL
via IFTTT